RT Journal Article
T1 Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection.
A1 Escudero-Sánchez, Rosa
A1 Ruíz-Ruizgómez, María
A1 Fernández-Fradejas, Jorge
A1 García Fernández, Sergio
A1 Olmedo Samperio, María
A1 Cano Yuste, Angela
A1 Valencia Alijo, Angela
A1 Díaz-Pollán, Beatriz
A1 Rodríguez Hernández, María Jesús
A1 Merino De Lucas, Esperanza
A1 Martín Segarra, Oriol
A1 Sáez Bejar, Carmen
A1 Armiñanzas Castillo, Carlos
A1 Gutiérrez Gutiérrez, Belén
A1 Rodríguez-Pardo, Dolors
A1 Ramos Martínez, Antonio
A1 De La Torre Cisneros, Julián
A1 López-Medrano, Francisco
A1 Cobo Reinoso, Javier
K1 C. difficile infection
K1 Clostridioides difficile
K1 Clostridium difficile
K1 bezlotoxumab
K1 recurrence
AB Bezlotoxumab is marketed for the prevention of recurrent Clostridioides difficile infection (rCDI). Its high cost could be determining its prescription to a different population than that represented in clinical trials. The objective of the study was to verify the effectiveness and safety of bezlotoxumab in preventing rCDI and to investigate factors related to bezlotoxumab failure in the real world. A retrospective, multicentre cohort study of patients treated with bezlotoxumab in Spain was conducted. We compared the characteristics of cohort patients with those of patients treated with bezlotoxumab in the pivotal MODIFY trials. We assessed recurrence rates 12 weeks after completion of treatment against C. difficile, and we analysed the factors associated with bezlotoxumab failure. Ninety-one patients were included in the study. The cohort presented with more risk factors for rCDI than the patients included in the MODIFY trials. Thirteen (14.2%) developed rCDI at 12 weeks of follow-up, and rCDI rates were numerically higher in patients with two or more previous episodes (25%) than in those who had fewer than two previous episodes of C. difficile infection (CDI) (10.4%); p = 0.09. There were no adverse effects attributable to bezlotoxumab. Despite being used in a more compromised population than that represented in clinical trials, we confirm the effectiveness of bezlotoxumab for the prevention of rCDI.
SN 2077-0383
YR 2020
FD 2020-12-22
LK https://hdl.handle.net/10668/28345
UL https://hdl.handle.net/10668/28345
LA en
DS RISalud
RD Apr 5, 2025